Consequently, diverse resistance research was conducted on the H1975 NSCLC cell line carrying the T790M mutation, and a third-generation EGFR-TKI, osimertinib (Tagrisso®), which targets T790M, has been approved by the United States Food and Drug Administration as first-line therapy for metastatic lung cancer patients with an EGFR exon 19 deletion or L858R mutation [3]. Here, EGFR is linked to non-small cell lung carcinoma.